Seres Therapeutics Inc (NASDAQ:MCRB) – Research analysts at Oppenheimer dropped their Q3 2020 earnings per share (EPS) estimates for shares of Seres Therapeutics in a report issued on Sunday, September 13th. Oppenheimer analyst M. Breidenbach now expects that the biotechnology company will earn ($0.22) per share for the quarter, down from their previous forecast of ($0.21). Oppenheimer currently has a “Buy” rating and a $29.00 target price on the stock. Oppenheimer also issued estimates for Seres Therapeutics’ Q4 2020 earnings at ($0.25) EPS, FY2020 earnings at ($1.02) EPS, Q1 2021 earnings at ($0.29) EPS, FY2021 earnings at ($1.24) EPS, FY2022 earnings at ($1.09) EPS and FY2023 earnings at ($0.23) EPS.
A number of other analysts also recently weighed in on the company. Canaccord Genuity upped their target price on Seres Therapeutics from $11.00 to $38.00 and gave the company a “buy” rating in a research report on Monday, August 10th. Jefferies Financial Group upgraded Seres Therapeutics from a “hold” rating to a “buy” rating and upped their price objective for the stock from $4.00 to $29.00 in a research report on Tuesday, August 11th. BidaskClub downgraded Seres Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, July 18th. HC Wainwright upped their price objective on Seres Therapeutics from $8.00 to $41.00 and gave the stock a “buy” rating in a research report on Tuesday, August 11th. Finally, Zacks Investment Research downgraded Seres Therapeutics from a “buy” rating to a “sell” rating in a research report on Thursday, July 30th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company’s stock. Seres Therapeutics currently has a consensus rating of “Buy” and an average target price of $30.64.
NASDAQ:MCRB opened at $27.32 on Wednesday. The stock has a fifty day moving average price of $18.90 and a 200-day moving average price of $7.86. The company has a market cap of $2.08 billion, a price-to-earnings ratio of -26.27 and a beta of 4.50. Seres Therapeutics has a fifty-two week low of $2.52 and a fifty-two week high of $33.00.
Seres Therapeutics (NASDAQ:MCRB) last issued its quarterly earnings data on Tuesday, July 28th. The biotechnology company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.02). The business had revenue of $6.05 million during the quarter, compared to analysts’ expectations of $9.67 million.
Large investors have recently made changes to their positions in the business. Cresset Asset Management LLC bought a new position in Seres Therapeutics in the second quarter worth approximately $58,000. Citigroup Inc. boosted its holdings in Seres Therapeutics by 15.0% in the first quarter. Citigroup Inc. now owns 15,802 shares of the biotechnology company’s stock worth $56,000 after acquiring an additional 2,060 shares in the last quarter. Trexquant Investment LP bought a new position in Seres Therapeutics in the second quarter worth approximately $318,000. Advisor Group Holdings Inc. bought a new position in Seres Therapeutics in the first quarter worth approximately $38,000. Finally, FDx Advisors Inc. bought a new position in Seres Therapeutics in the second quarter worth approximately $49,000. Institutional investors and hedge funds own 94.42% of the company’s stock.
About Seres Therapeutics
Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome. The company's advanced program is the SER-109, which is in Phase III clinical development for reducing recurrent clostridium difficile infection (CDI).
Featured Story: Trading signals using Bollinger bands
Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.